Genenta Science

Historical price data

Genenta Science is developing a disruptive immuno-gene therapy platform that engineers a patient's own hematopoietic stem cells to produce therapeutic proteins, like interferon-alpha, directly within the tumor microenvironment. This approach aims to overcome the limitations of systemic drug delivery by creating a sustained, localized anti-tumor effect with potentially reduced toxicity. The company's lead program, Temferon, is in Phase 1/2 clinical trials for glioblastoma multiforme, a highly aggressive brain cancer with limited treatment options. Genenta's strategy focuses on validating its platform in high-unmet-need oncology indications, with the potential to expand into other solid tumors and therapeutic areas.

Proprietary ex vivo gene therapy platform using lentivirally-transduced autologous hematopoietic stem/progenitor cells (HSPCs) to deliver therapeutic proteins specifically to the tumor microenvironment via differentiated myeloid cells.

3 drugs in pipeline

Total raised: $55M

Competes with other cell/gene therapy companies targeting solid tumors (e.g., CAR-T developers) and localized cytokine delivery approaches. Key differentiation is its use of engineered hematopoietic stem cells for durable, tumor-targeted delivery via the myeloid lineage, aiming for sustained effect with reduced systemic toxicity.